Cancer Care

 

 
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Principal Investigator (?)
Study Number
NSABP-B47
Summary
This randomized phase III clinical trial is studying chemotherapy with or without
trastuzumab after surgery to see how well they work in treating women with invasive breast
cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving more than one drug
(combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells.
Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or carry cancer-killing substances to them. It is not yet known whether combination
chemotherapy is more effective with trastuzumab in treating breast cancer.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Keene
Lebanon
Manchester
Southwestern Vermont

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.